

Porphyria Treatment Market 2026

<https://marketpublishers.com/r/P38804A47354EN.html>

Date: November 2025

Pages: 200

Price: US\$ 2,999.00 (Single User License)

ID: P38804A47354EN

Abstracts

The Porphyria Treatment Market was valued at in and is anticipated to reach by , at a CAGR of 0.092 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Porphyria Treatment Market.

This report delivers a comprehensive overview of the Porphyria Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Porphyria Treatment Market. The Porphyria Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

Porphyria Treatment Market Scope:

By Disease Type

Acute Porphyrias

Cutaneous Porphyrias

By Diagnosis

Blood test

Urine test

Genetic test

Others

By Treatment

Medications

Phlebotomy

Others

By End-user

Hospitals

Blood Centers

Others

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Key Players

Recordati Rare Diseases Inc.

AmerisourceBergen Corporation

Alnylam Pharmaceuticals, Inc.

CLINUVEL PHARMACEUTICALS LTD

sanofi-aventis U.S. LLC

Concordia Pharmaceuticals Inc.

AdvaCare Pharma

AuroMedics Pharma LLC(LIST NOT EXHAUSTIVE)

Major Highlights

This report delivers a comprehensive overview of the Porphyria Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Porphyria Treatment Market. The Porphyria Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest

of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the

privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. MARKET DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Market Snippet by Disease Type
- 3.2. Market Snippet by Diagnosis
- 3.3. Market Snippet by Treatment
- 3.4. Market Snippet by End user
- 3.5. Market Snippet by Distribution channel
- 3.6. Market Snippet by Region

4. MARKET DYNAMICS

- 4.1. Market Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Advancement in treating congenital Erythropoietic Porphyria is expected to drive market growth.
 - 4.1.2. Restraints:
 - 4.1.2.1. The high cost of the treatment is expected to hamper in the forecast period.
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Supply Chain Analysis
- 5.2. Pricing Analysis
- 5.3. Unmet Needs

6. COVID-19 ANALYSIS

- 6.1. Analysis of Covid-19 on the Market
 - 6.1.1. Before COVID-19 Market Scenario

- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid Covid-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion

7. BY DISEASE TYPE

- 7.1. Introduction
 - 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
 - 7.1.2. Market Attractiveness Index, By Disease Type Segment
- 7.2. Acute Porphyrias*
 - 7.2.1. Acute Intermittent Porphyria (AIP)
 - 7.2.2. Hereditary Coproporphyria (HCP)
 - 7.2.3. Variegate Porphyria (VP)
 - 7.2.4. ALAD-Deficiency Porphyria (ADP)
 - 7.2.5. Others
 - 7.2.6. Introduction
 - 7.2.7. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 7.3. Cutaneous Porphyrias
 - 7.3.1. Porphyria Cutanea Tarda (PCT)
 - 7.3.2. Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP)
 - 7.3.3. Congenital Erythropoietic Porphyria (CEP)
 - 7.3.4. Hepatoerythropoietic Porphyria (HEP)
 - 7.3.5. Others

8. BY DIAGNOSIS

- 8.1. Introduction
 - 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
 - 8.1.2. Market Attractiveness Index, By Diagnosis Segment
- 8.2. Blood test*
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 8.3. Urine test

8.4. Genetic test

8.5. Others

9. BY TREATMENT

9.1. Introduction

9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment

9.1.2. Market Attractiveness Index, By Treatment Segment

9.2. Medications*

9.2.1. Panhematin

9.2.2. GIVLAARI

9.2.3. SCENESSE

9.2.4. Hydroxychloroquine (Plaquenil)

9.2.5. Chloroquine (Aralen)

9.2.6. Others

9.2.7. Introduction

9.2.8. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%),
2021-2029

9.3. Phlebotomy

9.4. Others

10. BY END-USER

10.1. Introduction

10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

10.1.2. Market Attractiveness Index, By End user Segment

10.2. Hospitals*

10.2.1. Introduction

10.2.2. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%),
2021-2029

10.3. Blood Centers

10.4. Others

11. BY DISTRIBUTION CHANNEL

11.1. Introduction

11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11.1.2. Market Attractiveness Index, By Distribution Channel Segment

11.2. Hospital Pharmacies*

- 11.2.1. Introduction
- 11.2.2. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 11.3. Retail Pharmacies
- 11.4. Online Pharmacies
- 11.5. Others

12. BY REGION

- 12.1. Introduction
 - 12.1.1. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
 - 12.1.2. Market Attractiveness Index, By Region
- 12.2. North America
 - 12.2.1. Introduction
 - 12.2.2. Key Region-Specific Dynamics
 - 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
 - 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
 - 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
 - 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
 - 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
 - 12.2.8.1. U.S.
 - 12.2.8.2. Canada
 - 12.2.8.3. Mexico
- 12.3. Europe
 - 12.3.1. Introduction
 - 12.3.2. Key Region-Specific Dynamics
 - 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
 - 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
 - 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
 - 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
 - 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
 - 12.3.8.1. Germany
 - 12.3.8.2. U.K.
 - 12.3.8.3. France
 - 12.3.8.4. Italy
 - 12.3.8.5. Spain

12.3.8.6. Rest of Europe

12.4. South America

12.4.1. Introduction

12.4.2. Key Region-Specific Dynamics

12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis

12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment

12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

12.4.8.1. Brazil

12.4.8.2. Argentina

12.4.8.3. Rest of South America

12.5. Asia Pacific

12.5.1. Introduction

12.5.2. Key Region-Specific Dynamics

12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis

12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment

12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

12.5.8.1. China

12.5.8.2. India

12.5.8.3. Japan

12.5.8.4. Australia

12.5.8.5. Rest of Asia Pacific

12.6. Middle East and Africa

12.6.1. Introduction

12.6.2. Key Region-Specific Dynamics

12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis

12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment

12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

13. COMPETITIVE LANDSCAPE

13.1. Key Developments and Strategies

- 13.2. Company Share Analysis
- 13.3. Product Benchmarking
- 13.4. List of Key Companies to Watch

14. COMPANY PROFILES

- 14.1. Recordati Rare Diseases Inc.
 - 14.1.1. Company Overview
 - 14.1.2. Product Portfolio and Description
 - 14.1.3. Key Highlights
 - 14.1.4. Financial Overview
- 14.2. AmerisourceBergen Corporation
- 14.3. Alnylam Pharmaceuticals, Inc.
- 14.4. CLINUVEL PHARMACEUTICALS LTD
- 14.5. sanofi-aventis U.S. LLC
- 14.6. Concordia Pharmaceuticals Inc.
- 14.7. AdvaCare Pharma
- 14.8. AuroMedics Pharma LLC(*LIST NOT EXHAUSTIVE)

15. DATAM INTELLIGENCE

- 15.1. Appendix
- 15.2. About Us and Applications
- 15.3. Contact Us

I would like to order

Product name: Porphyria Treatment Market 2026

Product link: <https://marketpublishers.com/r/P38804A47354EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P38804A47354EN.html>